Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes
· First-in class drug candidate for type 2 diabetes stimulates glucose uptake in skeletal muscle, lowers blood glucose levels and treats comorbidities. · This novel pharmacological approach is supported by a recent clinical publication in Nature Communications*.
Solna, Sweden, January 25, 2023 – Atrogi AB (private) an early-stage Swedish pharma company today announced that the first patient has been enrolled in a Phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel ß\2\ adrenoceptor agonist with a unique mechanism of action for the treatment of type 2 diabetes